The present disclosure describes a novel therapeutic apheresis system and, more specifically, methods and an apparatus for performing therapeutic apheresis. The present disclosure provides highly efficient methods for therapeutic apheresis that modulate the immune system, thereby resulting in treatment of one or more underlying immunological disease processes. In some embodiments, the disclosed methods return at least a portion of blood from an extracorporeal circuit to a patient in pulsatile flow, where the portion of blood that is returned is augmented. In other embodiments, the disclosed methods and apparatus use the central arterial system to exchange volumes of plasma to immunomodulate disease processes. The disclosed methods combine concepts of intermittent flow and continuous flow therapeutic apheresis with established cardiovascular concepts. In addition, the disclosed methods reduce the amount of time spent by patients in therapeutic apheresis sessions and decrease patients' dependence on immunological drugs that may have detrimental adverse effects.

Disclosed embodiments relate to apparatuses and methods for wound treatment. A wound dressing apparatus can comprises a wound contact layer, at least one absorbent layer, an electronics unit comprising a negative pressure source unit, and a cover layer. The electronics unit can comprise a plurality of sensors positioned on a printed circuit board and an inlet protection mechanism of the negative pressure source unit comprises a first recess in fluid communication with a first sensor and the outlet or exhaust mechanism negative pressure source unit comprises a second recess in fluid communication with a second sensor.

In an aspect of the invention there is provided an insufflator apparatus for exposing structures within a cavity of the human body for a diagnostic and/or therapeutic endoscopic procedure, comprising: an insufflation gas supply valve, adapted to provide insufflation gas to a pressure regulator; the pressure regulator, adapted to supply insufflation gas into the cavity of the human body via an input mechanism attachable to the human body, a means for determining a pressure level in the body cavity; an insufflator vent mechanism adapted to release excess insufflation gas volume returning from the pressure regulator; an insufflator controller arranged to real-time adapt an insufflation rate of said insufflation gas via said gas supply valve and vent mechanism at a set average pressure level in the body cavity in accordance with the means for determining the pressure level in the body cavity; and wherein the pressure regulator has a limited volume for temporarily storing a gas returning from the body cavity to thereby avoid transient pressure deviations from the set average pressure level in the body cavity, e.g. due to coughing or mechanical ventilation and s allowing the gas to return to the body cavity to maintain the set average pressure.

A method for automatically detecting a clinically relevant leak and/or inadequate closure following a medical procedure, in a hollow organ residing in the interior volume of a body cavity. The test method includes the steps of: injecting, via an adapted injection element, a specific test gas or a gas mixture containing at least one test gas, into the organ, analyzing the gas mixture and measuring the test gas concentration in the interior volume of the body cavity via an adapted detection element and at least during a measurement window, evaluating the likelihood of the presence of a leak and its degree of severity, by comparing stored data and real-time data with each other. The pressure difference between the interior of the hollow organ(s) and the interior volume of the body cavity is controlled or mastered at least at a given moment during at least one measurement window.

A long-lasting, wireless, biocompatible pressure sensor device is integrated within a hydrocephalus shunt, either within the shunt's reservoir/anchor or as an inline or pigtailed connector. When integrated within a typical reservoir, the device can sit within the reservoir's hollow frustum area covered by the resilient silicone dome of the reservoir. When integrated as an inline connector, the device can sit at any point on the peritoneal catheter or ventricular catheter, including between the VP shut's valve and reservoir. The pressure sensor device includes electronics that can be powered wirelessly by a reader held to a patient's scalp, and so no battery may be required. The reader can transmit an ambient, atmospheric pressure reading from outside the skull to the implanted device so that its electronics can calculate a calibrated gauge pressure internally and then relay it to a patient's smart phone.

A catheter includes a tubular body to be inserted into a living body. The tubular body has a lumen that is held in fluid communication with an injection port defined in a distal end of the tubular body and a suction port near a proximal end of the tubular body, and the suction port is closed when the injection port is open, and the injection port is closed when the suction port is open.

A peritoneal dialysis cassette and an interface between the cassette and a peritoneal dialysis system is provided. The peritoneal dialysis cassette can include one or more fluid passages connecting a plurality of inlet/outlet ports, with one or more linear actuators usable to selectively direct fluid through the peritoneal dialysis cassette.

A sensor implant device includes a shunt structure comprising a flow path conduit and a plurality of arms configured to secure the shunt structure to a tissue wall, and a pressure sensor device attached to one of the plurality of arms of the shunt structure. The pressure sensor device comprises one or more sensor elements, an antenna, control circuitry electrically coupled to the one or more sensor elements and the antenna, and a housing that houses the control circuitry.

An injection system is described that receives, from one or more sensors, a first group of one or more signals indicating a current volume of injection fluid dispensed from a fluid reservoir at a first time. The injection system determines, based on the first group of one or more signals, that a difference between a dispensed volume limit and the current volume of the injection fluid dispensed from the fluid reservoir at the first time is less than a necessary volume of fluid required to complete both a systolic injection phase and a diastolic injection phase. The injection system further, responsive to determining that the difference is less than the necessary volume of fluid required to complete both the systolic injection phase and the diastolic injection phase, controls the injection system to refrain from performing each of the systolic injection phase and the diastolic injection phase.

A method includes applying, via a respiratory therapy system, initial therapy settings for a user during a first sleep session in which the user uses the respiratory therapy system. First physiological data, which is received from one or more sensors, is generated during the first sleep session. Modified therapy settings are applied, via the respiratory therapy system, during a second sleep session of the user. Second physiological data is received from the one or more sensors. The second physiological data is generated by the one or more sensors during the second sleep session. A set of sleep-related parameters is determined based on changes between the first physiological data and the second physiological data. One or more of a recommended therapy or recommended therapy settings is determined based on the set of sleep-related parameters.